SCHEMBL24370193

SCHEMBL24370193

Cc1cnn2ccc(Cl)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB3 P54753 5/20 0.43
PIK3CD O00329 2/20 0.39
PIK3CA P42336 2/20 0.39
PIK3CB P42338 2/20 0.39
CYP3A4 P08684 1/20 0.36
PTPN1 P18031 1/20 0.36
JAK2 O60674 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
PDE2A O00408 2/20 0.32
PDE10A Q9Y233 2/20 0.32
MAPT P10636 2/20 0.32
RAB9A P51151 2/20 0.32
LMNA P02545 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KCNH2 Q12809 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
KMO O15229 1/20 0.32
SMPD3 Q9NY59 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17133482 0.80 EPHB3 (0.43) EPHB3PIK3CDPIK3CAMAPTLMNA
SCHEMBL24149172 0.77 PIK3CA (0.44) PIK3CDPIK3CAPIK3CBSMPD3
SCHEMBL28626251 0.77 EPHB3 (0.43) EPHB3PIK3CDPIK3CAPIK3CBCYP3A4
SCHEMBL13178709 0.77 CASP1 (0.39) CYP3A4PDE10AMAPTLMNASMN1; SMN2
SCHEMBL24349062 0.77 PIK3CD (0.39) EPHB3PIK3CDPIK3CAPIK3CBRAB9A
SCHEMBL26067168 0.77 HTR2C (0.37) PIK3CDPIK3CAPIK3CBPDE2APDE10A
SCHEMBL24370197 0.77 EPHB3 (0.41) EPHB3PIK3CDPIK3CAPIK3CBPTPN1
SCHEMBL26719772 0.74 PIK3CA (0.34) PIK3CDPIK3CAPIK3CBLMNAKCNH2
SCHEMBL23938061 0.74 EPHB3 (0.46) EPHB3PIK3CAPDE2APDE10AMAPT
SCHEMBL17132526 0.74 LMNA (0.37) LMNASMPD3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365592-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2023-11-16 US disclosed
US-20230365592-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2023-11-16 US disclosed
WO-2023205475-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS CLOTHO, INC. (US) 2023-10-26 WO disclosed
WO-2023164233-A1 (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA AGIOS PHARMACEUTICALS, INC. (US) 2023-08-31 WO disclosed
WO-2022087634-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS CLOTHO, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365592-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 EPHB3 3578/4885PIK3CD 4599/4885PIK3CA 3008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.